Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIRAV R SHAH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1023148731
CMS profile
227258
Location
WYOMISSING, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$5,312.20

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $2,940.00 1
Travel and Lodging $1,405.29 11
Food and Beverage $966.91 42

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIRAV R SHAH

NPI 1023148731 · CMS profile ID 227258

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

WYOMISSING, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1023148731?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIRAV R SHAH, NPI 1023148731, CMS profile ID 227258. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023148731?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). NIRAV R SHAH, NPI 1023148731, CMS profile ID 227258. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023148731?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
NIRAV R SHAH, NPI 1023148731, CMS profile ID 227258, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1023148731?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $5,312.20 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $30.7301/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223924092 CMS
ABBVIE INC. $17.1901/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204192536 CMS
ABBVIE INC. $14.4501/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204192542 CMS
Ardelyx, Inc. $21.7601/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247882966 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,361.48 45
PY2020 $1,716.85 20
PY2021 $4,762.85 24
PY2022 $8,984.68 28
PY2023 $16,273.55 45
PY2024 $13,511.04 48
PY2025 $5,312.20 54

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,311.04 2
PY2025 Principal investigator $503,820.85 66
PY2024 Principal investigator $457,465.67 47
PY2023 Principal investigator $459,071.17 12
PY2022 Principal investigator $589,708.28 12
PY2021 Recipient $105.88 1
PY2021 Principal investigator $662,907.14 11
PY2020 Recipient $357.42 3
PY2020 Principal investigator $622,064.79 41
PY2019 Recipient $1,226.42 1
PY2019 Principal investigator $97,941.67 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 12/17/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773291
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 12/17/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773293
Recipient Eli Lilly and Company $915.38 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187872667
Recipient Eli Lilly and Company $1,395.66 12/17/2025 Covered Recipient Physician A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES No dispute reported 06/30/2026 1187872855
Principal investigator 1 Boehringer Ingelheim International GmbH $65.00 12/09/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773281
Principal investigator 1 ABBVIE INC. $189.18 12/04/2025 Non-covered Recipient Entity
REGIONAL GASTROENTEROLOGY ASSOCIATES OF LANCASTER LTD
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202528552
Principal investigator 1 ABBVIE INC. $8,936.30 11/05/2025 Non-covered Recipient Entity
REGIONAL GASTROENTEROLOGY ASSOCIATES OF LANCASTER LTD
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202521831
Principal investigator 1 Eli Lilly and Company $61,216.00 11/05/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN INC
LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1187884520
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773283
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773285
Principal investigator 1 Boehringer Ingelheim International GmbH $766.50 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773287
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773289
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773313
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773315
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773317
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 10/27/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773319
Principal investigator 1 Boehringer Ingelheim International GmbH $100.88 09/24/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773279
Principal investigator 1 Boehringer Ingelheim International GmbH $1,680.00 09/19/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773307
Principal investigator 1 Boehringer Ingelheim International GmbH $1,190.00 09/19/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773309
Principal investigator 1 Boehringer Ingelheim International GmbH $15,000.00 09/19/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773311
Principal investigator 1 GlaxoSmithKline, LLC. $1,874.07 09/09/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192144016
Principal investigator 1 GlaxoSmithKline, LLC. $1,662.35 08/18/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182358
Principal investigator 1 ABBVIE INC. $17,042.00 08/06/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) No dispute reported 06/30/2026 1202502324
Principal investigator 1 Boehringer Ingelheim International GmbH $100.88 07/28/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773305
Principal investigator 1 Boehringer Ingelheim International GmbH $1,680.00 07/18/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773273
Principal investigator 1 Boehringer Ingelheim International GmbH $15,000.00 07/18/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773275
Principal investigator 1 Boehringer Ingelheim International GmbH $1,190.00 07/18/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773277
Principal investigator 1 GlaxoSmithKline, LLC. $1,662.35 07/14/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182876
Principal investigator 1 ABBVIE INC. $130.66 07/02/2025 Non-covered Recipient Entity
REGIONAL GASTROENTEROLOGY ASSOCIATES OF LANCASTER LTD
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202494843
Principal investigator 1 GlaxoSmithKline, LLC. $4,298.77 06/12/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182871
Principal investigator 1 ABBVIE INC. $2,354.66 06/03/2025 Non-covered Recipient Entity
REGIONAL GASTROENTEROLOGY ASSOCIATES OF LANCASTER LTD
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202487957
Principal investigator 1 GlaxoSmithKline, LLC. $6,861.12 05/21/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182329
Principal investigator 1 GlaxoSmithKline, LLC. $698.28 04/28/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192144003
Principal investigator 1 GlaxoSmithKline, LLC. $175.00 04/28/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192144020
Principal investigator 1 GlaxoSmithKline, LLC. $6,152.52 04/28/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192144024
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 04/28/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182867
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773263
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773265
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773267
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773269
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773271
Principal investigator 1 Boehringer Ingelheim International GmbH $151.58 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773295
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773297
Principal investigator 1 Boehringer Ingelheim International GmbH $620.50 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773299
Principal investigator 1 Boehringer Ingelheim International GmbH $39.08 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773301
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 03/25/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220773303
Principal investigator 1 GlaxoSmithKline, LLC. $14,665.50 03/21/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182337
Principal investigator 1 Boehringer Ingelheim International GmbH $2.14 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773247
Principal investigator 1 Boehringer Ingelheim International GmbH $12.86 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773249
Principal investigator 1 Boehringer Ingelheim International GmbH $239.89 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773251
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773253
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773255
Principal investigator 1 Boehringer Ingelheim International GmbH $4.50 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773257
Principal investigator 1 Boehringer Ingelheim International GmbH $3.37 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773259
Principal investigator 1 Boehringer Ingelheim International GmbH $21.43 02/26/2025 Non-covered Recipient Entity
US Digestive Health At Wyomissing
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220773261
Principal investigator 1 GlaxoSmithKline, LLC. $9,729.59 02/24/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182333
Principal investigator 1 Eli Lilly and Company $47,241.00 02/12/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN INC
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187884468
Principal investigator 1 Eli Lilly and Company $578.60 02/10/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN INC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187885122
Principal investigator 1 GlaxoSmithKline, LLC. $848.42 01/31/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182354
Principal investigator 1 GlaxoSmithKline, LLC. $22,130.34 01/28/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192144007
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 01/28/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182346
Principal investigator 1 GlaxoSmithKline, LLC. $75.90 01/28/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182881
Principal investigator 1 Eli Lilly and Company $830.93 01/27/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN INC
A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) No dispute reported 06/30/2026 1187885120
Principal investigator 1 GlaxoSmithKline, LLC. $175.00 01/09/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192144012
Principal investigator 1 GlaxoSmithKline, LLC. $227.70 01/09/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182342
Principal investigator 1 GlaxoSmithKline, LLC. $375.00 01/09/2025 Non-covered Recipient Entity
USDH CLINICAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192182350
Principal investigator 1 Eli Lilly and Company $250,565.45 01/03/2025 Non-covered Recipient Entity
MEDICAL COLLEGE OF WISCONSIN INC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF LOXO-305 VERSUS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED BTK INHIBITOR NAIVE MANTLE CELL LYMPHOMA (BRUIN MCL-321) No dispute reported 06/30/2026 1187885698
Principal investigator 1 ABBVIE INC. $2,611.89 01/02/2025 Non-covered Recipient Entity
REGIONAL GASTROENTEROLOGY ASSOCIATES OF LANCASTER LTD
M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 1202434658

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $20,600.00 1
PY2024 Amount invested $0.00 1
PY2024 Value of interest $20,600.00 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $20,600.00 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $20,600.00 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $49,968.24 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

5 records · PY2021–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 CENTERLINE BIOMEDICAL INC. $0.00 $20,600.00 STOCK OWNERSHIP Physician Covered Recipient No dispute reported 06/30/2026 1251206528
PY2024 CENTERLINE BIOMEDICAL INC. $0.00 $20,600.00 STOCK OWNERSHIP Physician Covered Recipient No dispute reported 06/30/2026 1150286962
PY2023 Centerline Biomedical Inc. $0.00 $20,600.00 Stock Ownership Physician Covered Recipient No dispute reported 06/30/2026 1048554977
PY2022 Centerline Biomedical Inc. $0.00 $20,600.00 Stock Ownership Physician Covered Recipient No dispute reported 06/30/2026 953289153
PY2021 Centerline Biomedical Inc. $0.00 $49,968.24 Stock Ownership Physician Covered Recipient No dispute reported 06/30/2026 953289327